Clinical Significance of has_circ_0055625 in Colon Cancer Patients Undergoing FOLFOX Chemotherapy Treatment
Authors Liu X, Gao L, Shi S, Yang Y
Received 4 November 2020
Accepted for publication 23 December 2020
Published 22 January 2021 Volume 2021:14 Pages 221—227
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Xiuhua Liu, Liang Gao, Shaoxin Shi, Yun Yang
Department of Pathology, Xiamen Haicang Hospital, Xiamen, Fujian, 361000, People’s Republic of China
Correspondence: Xiuhua Liu
Department of Pathology, Xiamen Haicang Hospital, 89 Haiyu Road, Haicang District, Xiamen, Fujian 361000, People’s Republic of China
Objective: Colon cancer is a leading global cancer-related cause of morbidity and mortality. The oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (FOLFOX) regimen is a standard chemotherapeutic approach used to treat colon cancer. However, chemoresistant tumor cells typically lead to the emergence of recurrent FOLFOX-resistant tumors after initial treatment. As such, it is vital that novel approaches to identifying and eliminating such chemoresistant tumors be developed in an effort to improve patient chemotherapy outcomes.
Materials and Methods: In total, 100 samples of serum were obtained between April 2014 and April 2019 from patients who had been pathologically diagnosed with colon cancer from the Xiamen Haicang Hospital, and after these patients received FOLFOX chemotherapy treatment, serum samples were collected again. The expression of has_circ_0055625 in these serum samples was assessed via qPCR. Additionally, 5-FU IC50 values were detected via CCK-8 assay.
Results: We found has_circ_0055625 to be significantly upregulated in colon cancer patient serum. After FOLFOX treatment, chemotherapy-resistance was associated with the upregulation of has_circ_0055625.
Conclusion: In summary, these data may provide a foundation for future studies of chemotherapeutic resistance in patients undergoing FOLFOX treatment, potentially guiding treatment adjustment strategies. However, further work will be necessary to expand upon these findings.
Keywords: has_circ_0055625, colon cancer, chemotherapy resistance, FOLFOX chemotherapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]